≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Adrenomedullary hyperfunction

DOID Endpoint Browser PheWeb

E4_ADREMEDHYPER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E27.5
  • Hospital discharge: ICD-9 — 2556
  • Cause of death: ICD-10 — E27.5
  • Cause of death: ICD-9 — 2556

2 out of 7 registries used, show all original rules.

111

4. Check minimum number of events

None

111

5. Include endpoints

None

111

6. Filter based on genotype QC (FinnGen only)

109

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E27
Name in latin
Hyperfunctio medullae glandulae suprarenalis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 589 326 256
Only index persons 521 296 225
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 57.31 57.45 57.21
Only index persons 56.12 56.57 55.53

-FinnGen-

Key figures

All Female Male
Number of individuals 109 56 53
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 54.58 50.74 58.63

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
111
Matched controls
1110
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
140.4
103
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
852.6
78.3
68
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
+∞
77.4
65
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
165.9
53.7
53
6
TPH07
NOMESCO Finland
Cathetrisation of artery
11.7
31.1
39
49
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
27.2
25
*
8700/3-C74.9
ICD-O-3
Pheochromocytoma, NOS, of adrenal gland, NOS
+∞
26.1
24
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
23.8
22
*
H02AB09
ATC
hydrocortisone; systemic
47.8
21.9
26
7
C74.9
ICD-10 Finland
Malignant neoplasm: Adrenal gland, unspecified
+∞
20.4
19
*
8700/3-C74.1
ICD-O-3
Pheochromocytoma, NOS, of medulla of adrenal gland
+∞
18.2
17
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
17.1
16
*
ZXE10
NOMESCO Finland
More than one and less than three hours
4.5
14.1
65
264
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
52.9
12.2
14
*
BC1AD
NOMESCO Finland
CT of adrenal glands
36.4
10.6
13
*
BC5AQ
NOMESCO Finland
Chromaffine tissue SPECT with low dose CT
+∞
10.6
10
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
9.5
9
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
9.5
9
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.7
8.5
22
55
D35.59
ICD-10 Finland
Other paragangliom
+∞
8.4
8
*
C04AX02
ATC
phenoxybenzamine; oral
+∞
8.4
8
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
7.4
7
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
7.6
7.1
16
24
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
11.0
6.7
12
12
JN4AD
NOMESCO Finland
Body CT examination
4.1
6.7
20
56
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
73.9
6.5
7
*
H02AA02
ATC
fludrocortisone; oral
73.9
6.5
7
*
ZXE20
NOMESCO Finland
More than three and less than five hours
3.5
6.4
26
90
JN4BD
NOMESCO Finland
Extensive body CT
3.9
6.4
21
63
WX402
NOMESCO Finland
General anaesthesia
3.1
6.3
34
140
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
6.3
6
*
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
+∞
6.3
6
*
B01AB10
ATC
tinzaparin; parenteral
3.9
6.2
20
59
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.3
6.1
17
45

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
13
123.76
122.41
6.1
1.2
0.55
—
nmol/l
—
23
0
65
12
129.29
121.88
6.2
1.1
—
—
—
0
0
59
10
124.81
111.54
5.8
1.1
—
—
nmol/l
—
0
0
46
13
59.72
76.75
5.4
3.1
6.76
3.35
nmol/l
0.65
46
13
23
9
31.72
17.76
1.7
1.4
—
—
—
0
0
40
94
6.09
17.48
1.3
1.2
—
—
—
0
0
57
251
3.61
10.19
6.4
4.2
7.40
7.40
ph
0.51
21
44
71
400
3.15
7.82
8.8
7.0
1.20
1.21
mmol/l
0.45
56
342
21
59
4.16
6.99
7.2
3.4
1.23
1.22
mmol/l
0.30
21
53
67
410
2.60
5.63
13.9
8.7
0.00
0.00
e9/l
0.49
57
342
17
51
3.76
5.13
4.3
3.6
4.38
4.55
pmol/l
0.25
17
45
10
14
7.72
4.77
1.8
1.8
12.72
15.44
ug/l
—
10
14
25
103
2.84
4.54
8.2
6.8
105.12
103.99
mmol/l
0.63
25
103
48
283
2.23
4.01
2.1
2.3
—
—
—
0
0
23
100
2.64
3.74
1.3
1.2
—
—
—
0
0
25
115
2.52
3.63
5.8
6.0
1.02
1.04
mmol/l
0.19
25
106
19
76
2.81
3.61
5.8
7.0
—
—
—
0
0
54
345
2.10
3.59
2.1
1.9
—
—
—
0
0
31
159
2.32
3.55
3.4
3.1
157.26
130.91
ng/l
0.07
23
120
59
391
2.09
3.55
7.3
11.5
1.04
1.21
inr
3.18
25
111
71
516
2.04
3.19
6.7
4.2
6.45
6.69
mmol/l
0.47
71
476
33
183
2.14
3.10
2.7
2.8
575.30
553.95
mosm/kgh2o
0.19
27
164
14
52
2.94
3.02
5.1
4.7
24.54
25.09
mmol/l
0.27
14
52
42
260
1.99
2.92
3.0
2.8
—
—
—
0
0
50
332
1.92
2.82
3.2
3.5
164.52
35.26
e6/l
0.54
41
240
42
264
1.95
2.78
2.9
2.9
0.52
0.33
e6/l
0.41
37
200
36
217
1.98
2.67
5.6
4.6
—
—
—
0
0
9
26
3.67
2.54
4.4
2.8
—
—
—
0
0
24
127
2.14
2.51
1.4
1.3
—
—
—
0
0
11
39
3.02
2.42
6.6
7.8
—
—
—
0
0
6
13
4.81
2.30
5.2
2.3
—
—
—
0
0
43
288
1.80
2.26
3.0
2.9
67.31
252.02
e6/l
0.39
37
223
12
49
2.62
2.19
6.2
4.6
—
—
—
0
0
31
189
1.89
2.18
2.9
1.9
3.24
2.99
mg/l
0.32
26
168
23
127
2.02
2.14
2.9
2.3
11.20
14.07
umol/l
1.30
23
118
25
143
1.97
2.12
4.4
2.8
0.80
0.81
mmol/l
0.08
25
132
35
226
1.80
2.05
7.8
6.6
—
—
—
0
0
24
137
1.96
2.04
1.6
1.6
31.53
28.81
s
1.68
24
132
68
533
1.71
1.98
10.7
9.9
4.09
4.04
e9/l
0.09
59
472
95
823
2.07
1.96
24.8
15.6
14.64
14.70
%
0.04
95
815
6
16
3.90
1.96
1.0
1.0
—
—
—
0
0
6
16
3.90
1.96
1.0
1.1
—
—
—
0
0
5
11
4.70
1.96
4.0
2.2
—
—
—
0
0
6
17
3.67
1.86
3.2
2.2
8.07
8.72
kpa
—
6
17
6
17
3.67
1.86
3.2
2.2
5.25
4.92
kpa
—
6
17
13
60
2.32
1.86
1.3
1.3
85.71
111.37
iu/ml
—
7
22
37
250
1.72
1.84
2.1
3.0
—
—
—
0
0
19
104
2.00
1.81
1.8
1.7
—
—
—
0
0
8
31
2.70
1.69
8.0
4.2
—
—
—
0
0
6
20
3.11
1.60
1.2
1.5
—
—
—
0
0
29
197
1.64
1.38
1.6
1.5
19.78
22.18
nmol/l
0.34
29
164
5
17
3.03
1.37
4.2
1.9
25.78
24.22
mmol/l
—
5
17
5
17
3.03
1.37
4.0
1.9
8.06
8.54
kpa
—
5
17
58
465
1.52
1.34
7.4
6.1
0.19
0.19
e9/l
0.08
53
420
6
25
2.48
1.26
1.0
1.4
—
—
—
0
0
6
26
2.38
1.20
3.2
2.5
—
—
—
0
0
7
30
2.42
1.14
2.0
1.5
—
—
—
0
0
32
233
1.52
1.13
1.6
1.4
—
—
—
0
0
5
21
2.44
1.10
1.4
1.2
—
—
—
0
0
5
21
2.44
1.10
2.6
1.9
—
—
—
0
0
55
450
1.44
1.08
6.5
5.9
0.04
0.04
e9/l
0.31
46
401
56
460
1.44
1.08
6.4
6.0
1.78
1.77
e9/l
0.01
47
420
104
975
2.06
1.07
23.9
15.3
81.73
76.50
umol/l
0.47
104
975
55
451
1.44
1.07
6.4
5.9
0.58
0.57
e9/l
0.06
46
404
92
835
1.59
1.03
4.9
4.4
1.79
1.90
mu/l
0.40
85
750
32
238
1.48
1.02
3.5
3.9
0.00
0.00
estimate
-0.00
11
87
74
644
1.45
1.02
4.4
3.6
—
—
—
0
0
12
70
1.80
0.97
1.8
1.6
—
—
—
0
0
13
79
1.73
0.93
3.8
3.9
—
—
—
0
0
8
42
1.97
0.91
3.3
4.0
25.59
25.11
mmol/l
—
8
42
41
329
1.39
0.86
1.8
1.9
78.97
94.32
pmol/l
1.21
20
160
8
46
1.80
0.84
2.3
3.8
—
—
—
0
0
52
437
1.36
0.82
6.5
6.5
—
—
—
0
0
0
25
0.00
0.80
0.0
1.1
—
2.72
—
0
18
0
25
0.00
0.80
0.0
1.3
—
275.44
—
0
18
6
106
0.54
0.77
1.7
1.4
—
—
—
0
0
9
54
1.72
0.77
2.6
3.0
—
—
—
0
0
9
55
1.69
0.76
2.8
1.3
293.58
169.40
u/ml
—
9
47
13
88
1.54
0.64
1.5
1.7
—
—
—
0
0
40
334
1.31
0.63
4.6
3.8
26.70
37.77
ng/l
0.40
31
224
0
20
0.00
0.61
0.0
3.0
—
52.23
—
0
20
18
134
1.41
0.57
1.8
1.7
—
—
—
0
0
52
455
1.27
0.56
3.2
3.6
0.00
0.00
estimate
-0.00
13
94
6
96
0.60
0.55
1.2
1.4
—
—
—
0
0
102
983
1.46
0.46
20.4
12.3
—
—
—
0
0
15
113
1.38
0.45
1.5
1.4
440.00
561.54
titre
—
6
26
51
455
1.22
0.44
3.1
3.6
0.00
0.00
estimate
-0.00
13
84
0
15
0.00
0.41
0.0
2.3
—
68.32
—
0
15
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
7
105
0.64
0.41
1.1
1.4
—
—
—
0
0
8
60
1.36
0.41
2.3
2.6
10.16
9.83
g/l
—
8
54
96
919
1.33
0.41
19.2
13.1
23.58
21.67
mg/l
0.23
81
716
9
67
1.37
0.39
1.7
3.1
66.03
66.76
g/l
—
9
62
19
153
1.29
0.38
2.5
2.8
6.98
2.17
e6/l
0.56
13
81
50
451
1.20
0.37
3.9
5.0
0.00
0.00
estimate
-0.00
12
89
27
229
1.24
0.37
1.6
2.9
336.57
4274.23
umol/l
1.06
21
198
40
355
1.20
0.35
2.8
2.9
—
—
—
0
0
28
240
1.22
0.35
2.0
3.1
154.41
45.79
mg/l
0.42
20
157
7
53
1.34
0.31
2.1
2.0
—
—
—
0
0
11
85
1.33
0.29
1.9
3.7
—
—
—
0
0
8
64
1.27
0.28
3.5
4.8
—
—
—
0
0
21
179
1.21
0.27
1.8
1.9
—
—
—
0
0
15
124
1.24
0.25
1.7
1.8
—
—
—
0
0
29
258
1.17
0.24
2.9
3.1
—
—
—
0
0
5
37
1.37
0.24
2.8
1.4
34.60
47.11
nmol/l
—
5
37
5
38
1.33
0.23
2.4
2.0
1.48
1.62
g/l
—
5
33
29
260
1.16
0.22
3.2
3.6
16.51
7.43
mg/mmol
0.30
19
160
5
42
1.20
0.22
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
6
47
1.29
0.21
3.5
2.7
0.80
0.68
%
—
6
47
12
99
1.24
0.20
1.8
1.3
—
—
—
0
0
6
49
1.24
0.20
3.5
2.7
0.92
1.32
%
—
6
49
6
52
1.16
0.19
1.0
1.8
—
—
—
0
0
7
58
1.22
0.18
3.9
3.9
—
—
—
0
0
8
68
1.19
0.17
1.1
1.5
—
—
—
0
0
7
88
0.78
0.15
1.3
1.7
—
—
—
0
0
9
108
0.82
0.13
1.4
1.5
—
—
—
0
0
22
205
1.09
0.08
3.4
3.8
—
—
—
0
0
20
186
1.09
0.08
1.6
1.4
5.53
2.45
g/l
0.64
13
108
7
80
0.87
0.07
1.1
1.1
—
—
—
0
0
22
207
1.08
0.06
1.2
1.3
0.95
0.94
u/ml
—
6
55
25
262
0.94
0.05
1.6
1.6
1.68
1.39
mmol/l
1.03
20
226
15
159
0.93
0.03
1.2
1.2
61.49
25.77
iu/ml
—
7
49
61
618
0.97
0.02
3.7
4.1
—
—
—
0
0
26
258
1.01
0.00
3.0
3.6
—
—
—
0
0
18
183
0.98
0.00
3.2
2.8
1.08
0.70
ug/l
0.60
11
117
9
95
0.94
0.00
3.1
1.6
—
—
—
0
0
104
1038
1.03
-0.00
29.6
19.2
29.82
30.33
pg
2.20
104
1024
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
21.4
—
5.58
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
86.40
—
0
5
104
1039
1.02
-0.00
30.0
19.3
134.52
137.47
g/l
1.10
104
1026
0
8
0.00
-0.00
0.0
2.5
—
12.15
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
104
1038
1.03
-0.00
29.7
19.2
89.70
90.89
fl
2.24
104
1025
0
5
0.00
-0.00
0.0
6.6
—
0.65
—
0
5
0
8
0.00
-0.00
0.0
3.5
—
0.78
—
0
8
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
7.78
—
0
5
5
52
0.96
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
9.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
6.47
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
-0.00
1.8
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
15.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_ADREMEDHYPER and mortality.

Females

Parameter HR [95% CI] p-value
E4_ADREMEDHYPER 2.134 [1.49, 3.05] < 0.001
Birth year 0.993 [0.98, 1.0] 0.122

During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 254 females with E4_ADREMEDHYPER died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_ADREMEDHYPER.

N-year risk Females Males
1 0.217% No data
5 1.264% No data
10 2.879% No data
15 5.587% No data
20 9.629% No data

Relationships between endpoints

↥

Index endpoint: E4_ADREMEDHYPER – Adrenomedullary hyperfunction

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data